Abiopharma

🔍 Hughes Violetta (Executive)

Company: REPLIGEN CORP (RGEN)

Report Date: 2026-03-05

Detailed Transactions and Holdings:

• Acquired 2,466 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 6,608.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 277 shares of Common Stock at $170.02 per share (Direct)
  Date: 2026-09-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 6,331.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Ms. Hughes was awarded 2,466 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
• F2: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units.